Studies on the Action of Ethamsylate (Dicynene) on Haemostasis

Summary

Twelve healthy subjects received ethamsylate or a placebo by mouth over a 48 h period in a randomized double-blind trial. The template bleeding time (including estimation of amount of blood loss), platelet aggregation studies, and plasma levels of plasminogen, alpha₂-antiplasmin and fibronectin were carried out before and during treatment. The effect of a single dose (600 mg) of aspirin, given 24 h after commencement of treatment, was also determined.

Neither ethamsylate nor placebo caused a significant change in the basal values of any of the variables monitored but both the prolongation of the bleeding time and the amount of blood loss induced by aspirin were significantly less during ethamsylate treatment than with placebo. Ethamsylate failed to prevent the aspirin-induced elimination of the secondary wave of platelet aggregation.

We conclude that ethamsylate may reduce the haemorrhagic symptoms associated with mild functional platelet defects.

Keywords

Ethamsylate - Aspirin - Platelet aggregation - Template bleeding time

• References

• 1 Deacock AR de C, Birley DM. The anti-haemorrhagic activity of ethamsylate (Dicynene). Brit J Anaesthes 1969; 41: 18-24
• 2 Vinazzer H. Clinical and experimental studies on the action of ethamsylate on haemostasis and on platelet function. Thromb Res 1980; 19: 783-791
• 3 Morgan ME I, Benson JW T, Cooke RW I. Ethamsylate reduces the incidence of periventricular haemorrhage in very low birthweight babies. Lancet 1981; 11: 830-831
• 4 Jaffe G, Wickham A. A double-blind pilot study of Dicynene in the control of menorrhagia. J Internat Med Res 1973; 1: 127-129
• 5 Kasonde JM, Bonnar J. Effect of ethamsylate and aminocaproic acid on menstrual blood loss in women using intrauterine devices. Brit Med J 1975; 4: 21-22
• 6 Harrison RF, Campbell S. A double-blind trial of ethamsylate in the treatment of primary and intrauterine-device menorrhagia. Lancet 1976; 2: 283-285
• 7 Kovacs L, Annus J. Effectiveness of ethamsylate in intrauterine-device menorrhagia. Gynecol Obstet Invest 1978; 9: 161-165
• 8 Papatheodossiou N. Essai de la Dicynone en double aveugle dans des cas d’amygdalectomies. Med Hygiene 1973; 31: 1818-1819
• 9 Arora YR, Manford ML M. Operative blood loss and the frequency of haemorrhage associated with adenotonsillectomy in children: a double-blind trial of ethamsylate. Brit J Anaesthes 1979; 51: 557-561
• 10 Verstraete M, Tyberghein J, de Greef Y, Daems L, van Hoof A. Double-blind trials with ethamsylate, Batroxabin or tranexamic acid on blood loss after adenotonsillectomy. Acta Clinical Belgica 1977; 32: 136-141
• 11 Symes JM, Offen DM, Lyttle JA, Blandy JP, Chaput de Saintonge DM. The effect of Dicynene on blood loss during and after transurethral resection of the prostate. Brit J Urol 1975; 7: 203-207
• 12 Canal P. Ensayo comparativo de la accion ciclonamina y un placebo. Anales del Hospital de la Santa Cruz y San Pablo 1964; 24: 253-257
• 13 Louis J, Paulus JM. Essai d’un Nouvel Hémostatique: La Dicynone. Revue Médicale de Liège 1967; 22: 649-651
• 14 Kumar R, Ansell JE, Canoso RT, Deykin D. Clinical trial of a new bleeding time device. Am J Clin Pathol 1978; 70: 692-695
• 15 Hutton RA, Mikhailidis DP, Bernstein JY. et al Assessment of platelet function in patients with Raynaud’s syndrome. J Clin Pathol 1984; 37: 182-187
• 16 Laurell CB. Quantitative investigation of proteins by electrophoresis in agarose gel containing antibodies. Analyt Biochem 1966; 15: 45-52
• 17 Kovacs L, Falkay G. Ethamsylate as an inhibitor of prostaglandin biosynthesis in pregnant human myometrium in vitro. Experientia 1981; 37: 1182-1183